Scholarlink

Background <p>Peritoneal recurrence is a significant concern after curative resection of colorectal cancer (CRC), with systemic chemotherapy providing limited prevention. Prophylactic intraperitoneal chemotherapy (PIC) using platinum-based agents offers a potential strategy to reduce recurrence and improve survival.</p> Objective <p>Our objective was to assess the effectiveness of platinum-based PIC in reducing peritoneal recurrence and enhancing survival outcomes when administered during or after curative CRC resection versus surgery alone or standard systemic therapy.</p> Methods <p>We conducted a systematic review and meta-analysis following Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 2020 guidelines. Databases were searched from January 2015 to September 2025 for randomized and comparative studies of adults receiving curative CRC resection with platinum-based PIC versus controls. Primary outcomes were overall survival (OS), disease-free survival (DFS), and peritoneal recurrence. Secondary outcomes were grade 3–4 adverse events and major complications. Random-effects meta-analyses in R used hazard ratios (HRs) for time-to-event outcomes and risk ratios (RRs) for binary outcomes; heterogeneity was assessed via I<sup>2</sup>.</p> Results <p>In total, 16 studies were included in the qualitative synthesis and seven (three randomized controlled trials, four cohorts; <i>n</i>=1264) in the meta-analysis. Platinum-based PIC improved DFS (HR 0.57; 95% confidence interval [CI] 0.42–0.78, <i>p</i>=0.0004, I<sup>2</sup>=0%) and trended toward an OS benefit (HR 0.87; 95% CI 0.69–1.12, <i>p</i>=0.28, I<sup>2</sup>=0%). Peritoneal recurrence was reduced but heterogeneous (RR 0.69; 95% CI 0.29–1.63, <i>p</i>=0.40, I<sup>2</sup>=85%). No increases were observed in grade 3–4 events (RR 1.26; 95% CI 0.97–1.64, <i>p</i>=0.08, I<sup>2</sup>=0%) or complications (RR 1.02; 95% CI 0.74–1.39, <i>p</i>=0.91, I<sup>2</sup>=39%).</p> Conclusions <p>Platinum-based PIC appears to enhance DFS without increasing adverse events or complications. Larger randomized controlled trials with longer follow-up are needed to confirm potential survival benefits and determine optimal protocols.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Prophylactic Intraperitoneal Chemotherapy with Platinum Agents Following Curative Resection for Colorectal Cancer: A Systematic Review and Meta-Analysis

  • 期刊论文

  • 发表日期：

    2025年12月16日

查看全文
  • Ahmed Dawood Al Mahrizi,
  • Fatima Mossolem,
  • Erin Major,
  • Omar Elshafei,
  • Riddhi Machchhar,
  • Vishal Jain

摘要

Background

Peritoneal recurrence is a significant concern after curative resection of colorectal cancer (CRC), with systemic chemotherapy providing limited prevention. Prophylactic intraperitoneal chemotherapy (PIC) using platinum-based agents offers a potential strategy to reduce recurrence and improve survival.

Objective

Our objective was to assess the effectiveness of platinum-based PIC in reducing peritoneal recurrence and enhancing survival outcomes when administered during or after curative CRC resection versus surgery alone or standard systemic therapy.

Methods

We conducted a systematic review and meta-analysis following Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 2020 guidelines. Databases were searched from January 2015 to September 2025 for randomized and comparative studies of adults receiving curative CRC resection with platinum-based PIC versus controls. Primary outcomes were overall survival (OS), disease-free survival (DFS), and peritoneal recurrence. Secondary outcomes were grade 3–4 adverse events and major complications. Random-effects meta-analyses in R used hazard ratios (HRs) for time-to-event outcomes and risk ratios (RRs) for binary outcomes; heterogeneity was assessed via I2.

Results

In total, 16 studies were included in the qualitative synthesis and seven (three randomized controlled trials, four cohorts; n=1264) in the meta-analysis. Platinum-based PIC improved DFS (HR 0.57; 95% confidence interval [CI] 0.42–0.78, p=0.0004, I2=0%) and trended toward an OS benefit (HR 0.87; 95% CI 0.69–1.12, p=0.28, I2=0%). Peritoneal recurrence was reduced but heterogeneous (RR 0.69; 95% CI 0.29–1.63, p=0.40, I2=85%). No increases were observed in grade 3–4 events (RR 1.26; 95% CI 0.97–1.64, p=0.08, I2=0%) or complications (RR 1.02; 95% CI 0.74–1.39, p=0.91, I2=39%).

Conclusions

Platinum-based PIC appears to enhance DFS without increasing adverse events or complications. Larger randomized controlled trials with longer follow-up are needed to confirm potential survival benefits and determine optimal protocols.